Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Pharmacological profile of PNU-99194A, a D3-preferring dopamine antagonist, reviewed

Nov. 26, 1998

U.S. patent issues for conantokin-G and derivatives

Nov. 26, 1998

Antipsychotic drug dropped from Novartis pipeline

Nov. 25, 1998

Lilly's new glutamate receptor antagonists for pain

Nov. 25, 1998

Central alpha2-adrenoceptor antagonists claimed by Janssen for depression, Parkinson's disease

Nov. 25, 1998

Dopamine D3 receptor antagonists may provide clues about receptor function

Nov. 25, 1998

Tasmar sales suspended in Canada

Nov. 24, 1998

Synapton NDA is nonapprovable, FDA says

Nov. 24, 1998

Substituted heteroaromatic 5-ht1f agonists in development at Lilly as antimigraine agents

Nov. 24, 1998

Novel CRF1-specific ligands claimed by Neurogen

Nov. 24, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...